Albany, New York, September 19, 2017: Malignant Mesothelioma is a rare type of cancer that is caused because of exposure to toxic asbestos. The incidence of this cancer is high in countries such as China and Russia. These two countries are slated to be the most profitable markets for Malignant Mesothelioma, due to the fact that there is a relatively high production of asbestos in these two countries. Moreover, as the consumption of asbestos is high in the Asia Pacific, this region is expected to play a key role in providing opportunities to important players in the malignant mesothelioma market. Making available cheaper drugs by rapid substitution through generics is the main focus point in the global malignant mesothelioma market. . In order to understand this market in greater detail, the Market Research Reports Search Engine (MRRSE) has included a new report in its vast database named “Malignant Mesothelioma Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025).”
The research identifies that combination therapies application is gaining rapid prominence in the markets across regions. As the response rates of the current drugs used for the treatment of malignant mesothelioma are not high for the treatment of this rare form of cancer, new type of drugs are required to increase the present rate of survival. Players operating in this market are going in for acquisitions and collaborations in order to develop new molecules for the improved treatment of malignant mesothelioma. Companies are doing significant amount of R&D in order to develop new drugs for this disease.
In the global malignant mesothelioma market, the pemetrexed and combination segment is the major segment on the basis of drug type and is expected to represent about US$ 160 Mn, which translates to more than 45% share of revenue of the entire market in the year 2017. This is slated to touch a value of about US$ 300 Mn by the end of the period of assessment (2017-2025) and exhibit an 8.4% CAGR. Pemetrexed and combination segment is slated to gain more than 300 basis points in market share in the year 2025 over 2017. This is due to the fact that this segment exhibits a better response rate of about 30% to 40% when used singularly or in combination with other drugs. The pemetrexed and combination segment is the most lucrative segment and this trend is slated to sustain throughout the period of assessment. This segment is the most lucrative, demonstrating a market attractiveness index of 3.2 during the period of assessment.
Factors Driving the Growth of Pemetrexed and Combination Segment
Different types of combination therapies like those utilizing chemotherapy with cryotherapy, radio, targeted antibody or with other immunotherapies have the potential to improve the efficacy of different drugs. Such type of combination therapies tend to improve survival rates, which is backed by clinical data, as compared with only radiation therapies or surgeries. Hence, combination therapy is more effective in the treatment of malignant mesothelioma.
The Asia Pacific region is predicted to display the highest CAGR in the pemetrexed and combination drug type segment. Also, this segment is the most attractive in the Latin America market, displaying a market attractiveness index of 2.7. The pemetrexed and combination drug type segment is slated to display CAGRs of 9.5% and 7.5% respectively in the regions of Asia Pacific and Middle East and Africa.
Some of the leading companies in the global malignant mesothelioma market include Pfizer Inc., Boehringer Ingelheim GmbH, AstraZeneca Plc., Novartis AG, Bristol-Myers Squibb Company, Teva Pharmaceuticals, Sanofi, Eli Lilly and Company, Merck & Co., Inc. and F. Hoffmann-La Roche Ltd. among others.
Browse Full Global Malignant Mesothelioma Market Report with TOC : http://www.mrrse.com/malignant-mesothelioma-market
Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.
MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.
90, State Street
Albany, NY – 12207